Activation of the cytokine network and unfavorable outcome in patients with yellow fever

被引:75
作者
ter Meulen, J
Sakho, M
Koulemou, K
Magassouba, N
Bah, A
Preiser, W
Daffis, S
Klewitz, C
Bae, HG
Niedrig, M
Zeller, H
Heinzel-Gutenbrunner, M
Koivogui, L
Kaufmann, A
机构
[1] Univ Marburg, Dept Virol, Marburg, Germany
[2] Univ Marburg, Dept Med Biometry & Epidemiol, Marburg, Germany
[3] Univ Marburg, Dept Immunol, Marburg, Germany
[4] Robert Koch Inst, Dept Virol, D-1000 Berlin, Germany
[5] Univ Frankfurt Hosp, Inst Med Virol, Frankfurt, Germany
[6] Ctr Hosp Univ Donka, Projet Rech Fievres Hemorrag Guinee, Conakry, Guinea
[7] Inst Pasteur, Natl Reference Ctr Arboviruses & Viral Hemorrhag, Lyon, France
关键词
D O I
10.1086/425016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
To study the contribution of inflammatory mediators to the pathogenesis of yellow fever (YF), the serum levels of several cytokines and chemokines were measured in 7 patients with fatal YF (f-YF), 11 patients with nonfatal hemorrhagic YF (nf/h-YF), and 18 patients with nonfatal nonhemorrhagic YF (nf/nh-YF). The levels of interleukin (IL)-6, monocyte chemoattractant protein-1, interferon-inducible protein (IP)-10, tumor necrosis factor-alpha, and IL-1 receptor antagonist (IL-1RA) were all statistically significantly higher in the patients with f-YF than in those with nf/nh-YF. In patients with nf/h-YF, only levels of IP-10 and IL-1RA were significantly elevated. The high levels of pro- and anti-inflammatory cytokines and chemokines in serum from patients with f-YF are reminiscent of those seen in patients with bacterial sepsis. This finding has implications for the understanding of the pathophysiology of YF and the development of therapeutic strategies.
引用
收藏
页码:1821 / 1827
页数:7
相关论文
共 37 条
[1]
Inflammatory responses in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges, AJ ;
Georges-Courbot, MC ;
Capron, M ;
Bedjabaga, I ;
Lansoud-Soukate, J ;
Mavoungou, E .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 128 (01) :163-168
[2]
BEEUWKES H, 1936, T R SOC TROP MED HYG, V1, P61
[3]
Biron CA, 1999, CURR OPIN MICROBIOL, V2, P374
[4]
Ebola hemorrhagic fever and septic shock [J].
Bray, M ;
Mahanty, S .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (11) :1613-1617
[5]
A Belgian traveler who acquired yellow fever in the Gambia [J].
Colebunders, R ;
Mariage, JL ;
Coche, JC ;
Pirenne, B ;
Kempinaire, S ;
Hantson, P ;
Van Gompel, A ;
Niedrig, M ;
Van Esbroeck, M ;
Bailey, R ;
Drosten, C ;
Schmitz, H .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) :E113-E116
[7]
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event [J].
Geisbert, TW ;
Young, HA ;
Jahrling, PB ;
Davis, KJ ;
Kagan, E ;
Hensley, LE .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (11) :1618-1629
[8]
Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options [J].
Gogos, CA ;
Drosou, E ;
Bassaris, HP ;
Skoutelis, A .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :176-180
[9]
In vivo synthesis of tumor necrosis factor-α in healthy humans after live yellow fever vaccination [J].
Hacker, UT ;
Jelinek, T ;
Erhardt, S ;
Eigler, A ;
Hartmann, G ;
Nothdurft, HD ;
Endres, S .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (03) :774-778
[10]
Medical progress: The pathophysiology and treatment of sepsis. [J].
Hotchkiss, RS ;
Karl, IE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) :138-150